Pain Control for Undergoing Costal Cartilage Harvesting

Conditions

• Nasal Surgery

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Exparel — DRUG
  106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
• Xylocaine — DRUG
  8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site

Study Details

The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.

Key Dates

Start date

May 4, 2022

Status verified

Sep 2025

Primary completion

Aug 31, 2026

Completion

Sep 30, 2026

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Exparel® Injection Group
  On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Exparel®
• Active Comparator: Xylocaine® Injection Group
  On the day of clinically indicated nasal surgery the surgical wound on the chest, where the rib cartilage is removed, will be injected with Xylocaine® as part of standard of care.

Primary Outcome Measure

Pain Scores [ Time Frame: 7-10 days following the last administration of study treatment ]

Central Contacts

• Amy Tuchscherer
  507-538-6582
  [email protected]

Locations (1)

Find similar trials in Rochester, MN